Daniel P. Cahill

34.6k total citations · 4 hit papers
176 papers, 9.7k citations indexed

About

Daniel P. Cahill is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Daniel P. Cahill has authored 176 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Genetics, 43 papers in Pulmonary and Respiratory Medicine and 43 papers in Cancer Research. Recurrent topics in Daniel P. Cahill's work include Glioma Diagnosis and Treatment (110 papers), Meningioma and schwannoma management (34 papers) and Brain Metastases and Treatment (30 papers). Daniel P. Cahill is often cited by papers focused on Glioma Diagnosis and Treatment (110 papers), Meningioma and schwannoma management (34 papers) and Brain Metastases and Treatment (30 papers). Daniel P. Cahill collaborates with scholars based in United States, Germany and Japan. Daniel P. Cahill's co-authors include Kenneth W. Kinzler, Bert Vogelstein, Christoph Lengauer, David N. Louis, Gregory J. Riggins, Sanford D. Markowitz, James K. V. Willson, A. John Iafrate, Hiroaki Wakimoto and Jian Yu and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Daniel P. Cahill

161 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations of mitotic checkpoint genes in human cancers

1998 1.2k citations Daniel P. Cahill, Gregory J. Riggins et al. profile →
Genetic instability and darwinian selection in tumours

1999 546 citations Daniel P. Cahill, Kenneth W. Kinzler et al. profile →
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

2011 498 citations Daniel P. Cahill, Rebecca A. Betensky et al. profile →
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

2019 426 citations Bryan D. Choi, Brian V. Nahed et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel P. Cahill United States	44	4.3k	4.2k	2.5k	2.5k	1.5k	176	9.7k
Howard Colman United States	46	5.8k 1.3×	6.1k 1.5×	3.8k 1.5×	2.9k 1.2×	1.8k 1.2×	151	11.8k
Matija Snuderl United States	40	3.2k 0.7×	2.6k 0.6×	2.2k 0.9×	2.2k 0.9×	1.4k 0.9×	188	9.2k
Erik P. Sulman United States	52	5.2k 1.2×	3.7k 0.9×	3.1k 1.2×	2.4k 1.0×	2.1k 1.5×	223	10.5k
Ryo Nishikawa Japan	40	3.3k 0.8×	4.3k 1.0×	1.9k 0.8×	2.1k 0.8×	1.7k 1.2×	201	8.4k
Jason T. Huse United States	50	6.2k 1.4×	4.8k 1.1×	3.6k 1.5×	2.9k 1.2×	1.3k 0.9×	131	12.3k
Koichi Ichimura Japan	49	4.1k 1.0×	4.4k 1.0×	2.3k 0.9×	2.5k 1.0×	1.3k 0.9×	263	9.3k
Frank B. Furnari United States	52	7.9k 1.8×	3.0k 0.7×	3.0k 1.2×	3.1k 1.2×	1.1k 0.8×	127	12.0k
Emmanuelle di Tomaso United States	41	5.2k 1.2×	2.1k 0.5×	2.8k 1.1×	4.2k 1.7×	1.8k 1.2×	90	11.1k
D. Williams Parsons United States	31	5.3k 1.2×	4.7k 1.1×	3.3k 1.3×	1.9k 0.8×	1.3k 0.9×	92	10.2k
Hai Yan United States	37	7.1k 1.7×	5.5k 1.3×	4.6k 1.9×	2.2k 0.9×	2.0k 1.3×	91	12.5k

Countries citing papers authored by Daniel P. Cahill

Since Specialization

Citations

This map shows the geographic impact of Daniel P. Cahill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Cahill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Cahill more than expected).

Fields of papers citing papers by Daniel P. Cahill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel P. Cahill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Cahill. The network helps show where Daniel P. Cahill may publish in the future.

Co-authorship network of co-authors of Daniel P. Cahill

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Cahill. A scholar is included among the top collaborators of Daniel P. Cahill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Cahill. Daniel P. Cahill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramapriyan, Rishab, María Martínez-Lage, Julie J. Miller, et al.. (2024). Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma. Clinical Cancer Research. 30(18). 4068–4076. 4 indexed citations

Karschnia, Philipp, J. C. Tonn, & Daniel P. Cahill. (2024). The Infiltrative Margins in Glioblastoma: Important Is What Has Been Left behind. Clinical Cancer Research. 30(21). 4811–4812. 3 indexed citations

Higuchi, Fumi, Hiroaki Nagashima, Jianfang Ning, et al.. (2020). Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clinical Cancer Research. 26(7). 1690–1699. 88 indexed citations

Nagashima, Hiroaki, Christine K. Lee, Kensuke Tateishi, et al.. (2020). Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discovery. 10(11). 1672–1689. 43 indexed citations

Park, Jong‐Whi, Felix Sahm, Isabel Arrillaga‐Romany, et al.. (2020). TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro-Oncology. 23(1). 76–87. 27 indexed citations

Ippen, Franziska M., Christopher Alvarez‐Breckenridge, Benjamin M. Kuter, et al.. (2019). The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA -Mutant Breast Cancer Brain Metastases. Clinical Cancer Research. 25(11). 3374–3383. 61 indexed citations

Juratli, Tareq A., Pamela S. Jones, Nancy Wang, et al.. (2019). Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 125(17). 2910–2914. 66 indexed citations

Higuchi, Fumi, Alexandria L. Fink, Juri Kiyokawa, et al.. (2018). PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency–Mediated Acquired Resistance to Temozolomide. Molecular Cancer Therapeutics. 17(12). 2551–2563. 28 indexed citations

Tateishi, Kensuke, Fumi Higuchi, Julie J. Miller, et al.. (2017). The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1 -Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity. Cancer Research. 77(15). 4102–4115. 73 indexed citations

10.

Esaki, Shinichi, Fares Nigim, Juri Kiyokawa, et al.. (2017). Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models. International Journal of Cancer. 141(11). 2348–2358. 37 indexed citations

11.

Miller, Julie J., Helen A. Shih, Ovidiu C. Andronesi, & Daniel P. Cahill. (2017). Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications. Cancer. 123(23). 4535–4546. 100 indexed citations

12.

Tateishi, Kensuke, A. John Iafrate, Quan Ho, et al.. (2016). Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clinical Cancer Research. 22(17). 4452–4465. 119 indexed citations

13.

Marusyk, Andriy, Doris P. Tabassum, Michalina Janiszewska, et al.. (2016). Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research. 76(22). 6495–6506. 96 indexed citations

14.

Andronesi, Ovidiu C., Franziska Loebel, Wolfgang Bogner, et al.. (2015). Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research. 22(7). 1632–1641. 116 indexed citations

15.

Wakimoto, Hiroaki, Shota Tanaka, William T. Curry, et al.. (2014). Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas. Clinical Cancer Research. 20(11). 2898–2909. 130 indexed citations

16.

Patel, Anoop P., Itay Tirosh, John J. Trombetta, et al.. (2014). Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344(6190). 1396–1401. 186 indexed citations

17.

Bettegowda, Chetan, Nishant Agrawal, Yuchen Jiao, et al.. (2011). Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma. Science. 333(6048). 1453–1455. 370 indexed citations

18.

Dziurzynski, Kristine, Jun Wei, Wei Qiao, et al.. (2011). Glioma-Associated Cytomegalovirus Mediates Subversion of the Monocyte Lineage to a Tumor Propagating Phenotype. Clinical Cancer Research. 17(14). 4642–4649. 111 indexed citations

19.

Yip, Stephen, Jiangyong Miao, Daniel P. Cahill, et al.. (2009). MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. Clinical Cancer Research. 15(14). 4622–4629. 292 indexed citations

20.

Cahill, Daniel P., Kymberly K. Levine, Rebecca A. Betensky, et al.. (2007). Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment. Clinical Cancer Research. 13(7). 2038–2045. 330 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact